key: cord-0852625-ltp2785d authors: Zheng, Caifang; Shao, Weihao; Chen, Xiaorui; Zhang, Bowen; Wang, Gaili; Zhang, Weidong title: Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis date: 2021-11-17 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.11.009 sha: 167455a4bb36cd43c01d41129fa73ce84e1a5c76 doc_id: 852625 cord_uid: ltp2785d Objectives To estimate the COVID-19 vaccine effectiveness (VE) against concerned outcomes in real-world settings. Methods We included studies reported the COVID-19 VE from August 6, 2020, to October 6, 2021. We estimated the summary VE with 95% confidence intervals (95% CIs) against disease related to COVID-19. The results were presented in forest plots. Predefined subgroup analysis and sensitivity analysis was also performed. Results 51 records were included in this meta-analysis. In the full vaccination, the VE against SARS-CoV-2 infection, COVID-19 related hospitalization, admission to ICU, and death were 89.1% (95% CI, 85.6 to 92.6), 97.2% (95% CI, 96.1 to 98.3), 97.4% (95% CI, 96.0 to 98.8) and 99.0% (95% CI, 98.5 to 99.6), respectively. It showed that the VE against infection for general population aged 16 years or older, the elderly and health care workers (HCWs) were 86.1% (95% CI, 77.8 to 94.4), 83.8% (95% CI, 77.1 to 90.6) and 95.3% (95% CI, 92.0 to 98.6), respectively. For full vaccination against infection, 91.2% effectiveness of the Pfizer-BioNTech vaccine and the 98.1% effectiveness of Moderna vaccine were observed, while 65.7% effectiveness of the CoronaVac were reported. Conclusions The COVID-19 vaccines are highly protective against SARS-CoV-2 related diseases in the real-world settings. Globally, as of 15 October 2021, there have been more than 239.4 million confirmed cases of Coronavirus disease 2019 , including over 4.8 million deaths (WHO, 2021b) . Science the outbreak of COVID-19, several vaccines have been tested and granted for emergency use authorization. Phase III trials reported high vaccine effectiveness (VE) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with these vaccines, such as 70.4% effectiveness of the ChAdOx1 nCoV-19 (AZD1222; Oxford-AstraZeneca) vaccine (Voysey et al., 2021) , 95% effectiveness of the BNT162b2 mRNA vaccine (Skowronski and De Serres, 2021) , 94.1% effectiveness of the mRNA-1273 (Moderna) vaccine (Baden et al., 2021) , and 50.7% effectiveness of the absorbed COVID-19 (inactivated) vaccine (Corona Vac) (Palacios et al., 2020) . Given that the outcomes in clinical trials may be influenced by various study settings, it is necessary to estimate the effectiveness of vaccines rolled out to the public in the real-world. Recently, a series of studies have reported real-world VE all over the world. A nationwide mass vaccination setting in Israel showed 92% effectiveness for documented infections after the second dose of the BNT162b2 vaccine (Dagan et al., 2021) . The UK government has adopted a strategy of delaying the second dose to increase the vaccine coverage, which suggested a 51.4% VE against SARS-CoV-2 infections after 1 dose of the BNT162b2 vaccine (Chodick et al., 2021) . 73% effectiveness against COVID-19 cases was observed among the elderly after vaccination with 1 dose of the ChAdOx1 vaccine in England(Lopez Bernal et al., 5 2021) . In Chile, the Sinovac vaccine rolled out to the general population aged 16 or older showed an effectiveness of 16.13% after the first dose and 66.96% after the second dose. (Salud., 2021) The World Health Organization (WHO) notes that there is an urgent need for COVID-19 VE against several major outcomes, including symptomatic COVID-19, severe diseases, and death related to COVID-19 (Patel et al., 2021) . Therefore, we conducted this review and meta-analysis to estimate the COVID-19 VE against concerned outcomes in real-world settings based on the latest evidence. For this literature review and meta-analysis, we searched systematically in PubMed, using the terms "COVID-19" or "SARS-CoV-2" and "vacc*" and "eff*" for articles published August 6, 2020 (Deplanque and Launay, 2021) to October 6, 2021 in countries where are vaccinated. In addition, we searched major news media platforms to track reports from governments and health authorities around the world evaluating the effectiveness of the COVID-19 vaccine. The review process is described in detail in Figure 1 . Observational study (cohort, case-control, test-negative case-control) were included. Studies reporting exclusively on the immunogenicity of COVID-19 vaccine, review articles, data only in abstract form, ecological study, mathematical modeling analysis studies were excluded. If two or more articles and reports presented results from the 6 same dataset, all articles that included unique data points by the vaccine, study population, or vaccination status were included. In situations where findings in one article were a subset of findings from another article (e.g., study sites and population) only the most comprehensive article was included in the overall analysis, but the subset was included in subgroup analysis. At least 2 reviewers examined articles to confirm inclusion criteria were satisfied and to reach consensus when necessary. Data were extracted by two independent authors in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA) (Page et al., 2021) and the checklist was presented in Supplement table1. We abstracted summary VE, stratified VE estimates by COVID-19 vaccine against a range of SARS-CoV-2 outcomes (confirmed SARS-CoV-2 infection with reverse transcription-polymerase chain reaction (rt-PCR), and COVID-19 related hospitalization, admission to the ICU and severe or critical hospitalization, and death) in partial and full vaccination (in view of the status of partial and full vaccination of individuals varied with the recommendations of the health authorities in different countries and regions, we relied on those reported in the literature and included analysis of the results.), vaccine brand and study population; characters of the studies, such as study design, study population, and sample size, into a Microsoft Excel database. Descriptive statistics and percentages were calculated for the article attributes. We estimated the real-world effectiveness of COVID-19 vaccines against a range of SARS-CoV-2 outcomes in partial and full vaccination status, vaccinated population, and vaccines brand. Estimates of VE expressed as percentage (%) as well as their 95% confidence intervals (95% CIs) were derived from the effect measures (odds ratios, relative risks, hazard ratios, and incidence rate ratios) using VE = [1-effect measure] × 100. VE estimates > 0% suggest a protective effect. The results were presented in forest plots. Heterogeneity of outcomes across studies was assessed with the I 2 statistics and be quantified as low (≤ 25%), moderate (25% ~ 50%), and high (>50%). A random-effects model was used when I 2 statistics > 25% in the data. Otherwise, fixed-effects model was chosen. Conducting stratified meta-analyses explore potential sources of study heterogeneity. The Newcastle-Ottawa scale (NOS) (range from 0 to 9 points) was used to assess the quality of included observational studies, and a higher total NOS score suggests better quality (Wells. et al.) . The influence of inclusion of a study on the results of this meta-analyses was assessed using sensitivity analysis. Additionally, we used Egger's test and a funnel plot of the standard error, sampling variance, and the inverse of the standard error and sampling variance to evaluate the publication bias with 10 or more included articles. Analyses were conducted in R software (version 4.1.0; The R Foundation) using the metafor package for meta-analyses ('metafor', 2021) . For this literature review, we identified and screened 13018 records, of which 13016 were in PubMed, and 2 reports from the official website of the government health department. 12645 were not relevant to the research question based on title and were excluded ( Figure 1 ). Abstracts were reviewed for the remaining 115 articles and 2 reports. 59 articles were read in full; an additional 7 were excluded because they did not meet our methodological inclusion criteria. One report did not provide information on the time span of vaccination, age, and health status of the vaccinated persons, and was therefore excluded. In total, 50 articles and 1 report were included from 14 countries including 38821141 individuals. In the partly immunized status, 38, 12, 3, and 8 articles of included studies reported VE against SARS-CoV-2 infection, COVID-19 related hospitalization, ICU admission or severe disease, and death, respectively. The summary VE was 68.8% (95% CI, 60.1 to 77.5) for the prevention of SARS-CoV-2 infection and 67.8% (95% CI, 51.6 to 83.9) for the prevention of hospitalization, 66.4% (95% CI, 25.9 to 100.0) for the prevention of admission to the ICU and severe disease, and 58.4% (95% CI, 28.0 to 88.7) for the prevention of COVID-19 related death (Supplement figure 4-5) . The In this review including 51 latest records from 14 countries reported on the effectiveness of COVID-19 vaccines, we estimated the VE against disease with laboratory-confirmed SARS-CoV-2 infection, COVID-19 related hospitalization, admission to ICU, and death. We presented the estimates of VE against infection with subgroup analyses for vaccine brands, vaccinated population, and vaccinated status. The results suggested that the vaccines currently approved for use have a good protective effect against the major outcomes related to COVID-19, especially for critical outcomes. It's noted that there was high heterogeneity for the summary VE against SARS-CoV-2 infection among fully vaccinated individuals. In addition to the actual effectiveness of the different vaccines, population effectiveness evaluation depends on a series of factors, such as the vaccinated population, the severity of the epidemic, the completeness and validity of the data sources, study design and potential methodological biases (Patel et al., 2021) . Therefore, we performed subgroup analysis and sensitivity analysis to explore the potential heterogeneity. Consistent with the results of phase III clinical trials, the effectiveness of different vaccines against confirmed infection in real-world conditions varied (Baden et al., 2021 , Palacios et al., 2020 , Skowronski and De Serres, 2021 , Voysey et al., 2021 . Synthesized evidence from different study settings showed 91.2%, 98.1%, and 65.7% effectiveness of the Pfizer-BioNTech vaccine, the Moderna vaccine, and the Corona Vac, respectively. For full vaccination, lower VE against COVID-19 related hospitalization and severe disease were observed when deleting the results conducted by Eric J Haas, et al (Haas et al., 2021) . The study with a high quality revealed that two doses of BNT162b2 are highly effective across all age groups in Israel based on nationwide surveillance data. Vac. , Salud., 2021 The VE of Corona Vac, an inactivated whole virus vaccine, may be influenced in the settings of high SARS-CoV-2 Gamma 13 variant transmission, whether in Brazil or Chile. (Jara et al., 2021 , Palacios et al., 2020 Similarly, VE is closely related to vaccination status. Subgroup analysis by vaccination status revealed that 66.8%, 67.8%, 66.4 and 58.4% effectiveness of partial vaccination against disease with confirmed infection, COVID-19 related hospitalization, severe diseases, and death, respectively, despite less effective than full vaccination. Therefore, this finding supports the proposal across many countries of extending dosing interval to optimize the vaccine coverage with the increasing number of new infections and the spread of SARS-CoV-2 variants (Chodick et al., 2021 , Krutikov et al., 2021 , Shrotri et al., 2021 . Besides, several studies showed higher VE for longer periods of time since vaccination, whether for partial or full vaccination. (Jones et al., 2021 , Rudolph et al., 2021 , Zaqout et al., 2021 Given the highest mortality observed in the elderly of long-term care facilities and higher exposure risk for health care workers (Team, 2020 , Wu and McGoogan, 2020 , Zhou et al., 2020 , many countries have prioritized both high-risk groups for vaccinations (Britton et al., 2021 , Lopez Bernal et al., 2021 . However, elderly patients are less represented in clinical trials which mainly enrolled young population (Prendki et al., 2020) . We synthesized evidence in real-world by vaccinated population. The most protective effect was seen in the health care workers (VE = 95.3%), while less VE was observed in the elderly (VE = 83.8%). Due to immunosenescence and comorbidities, the elderly are more susceptible to infections and have poor responses to vaccination (Brosh-Nissimov et al., 2021 , Ciabattini et al., 2018 , Frasca et al., 2010 , 14 McElhaney et al., 2013 . Therefore, more measures for the elderly than vaccination need to be implemented to reduce the severe outcomes related to infections and control the transmission in the care facilities. Nevertheless, there are some limitations to this meta-analysis. Firstly, we were unable to estimate the long-term effectiveness of vaccines due to the limited length of follow-up. A test-negative case-control study conducted in England, protection of fully vaccinations with the Oxford-AstraZeneca vaccine in the elderly was maintained from the second week (VE=22.0%, 95%CI, 11.0 to 32.0) after vaccination to the end of the follow-up (more than 6 weeks) (VE=73.0%, 95%CI, 27.0 to 90.0)(Lopez Bernal et al., 2021) . In the Mayo Clinic health system, the effectiveness after the second dose of the Pfizer-BioNTech vaccine or the Moderna vaccine increased from 53.6% (95%CI, 40.9 to 63.8) in the first week to 92.5% (95%CI, 70.2 to 99.1) in the sixth week (Pawlowski et al., 2021) . Based on available evidence, there is increased VE within 6 weeks after full vaccination, but it is difficult to reveal the peak effectiveness and actual duration of immunization protection. Secondly, we didn't estimate the VE against infectiousness to others. A retrospective cohort study in the US suggested 80.0% (95%CI, 91.0 to 56.0) effectiveness against infectiousness to others after the second dose of the Pfizer-BioNTech vaccine (Tande et al., 2021) . In addition, a single dose of the Moderna vaccine was estimated to reduce the potential transmission to others by 61.0% (95%CI, 31.0 to 79.0) (Lipsitch and Kahn, 2021) . The vaccine could reduce the risk of transmission, but further studies are needed to assess the actual VE for every vaccine. Thirdly, the emergence of SARS-CoV-2 variants caused increase severe infections (Gomez et al., 2021) , and four dominant Variants of Concern (VOCs) were B.1.1.7 (Alpha, UK, Sep-2020), B.1.351 (Beta, South Africa, May-2020), P.1 (Gamma, Brazil, Nov-2020) and B.1.617.2 (Delta, India, Oct-2020) (WHO, 2021a) . Several clinical trials have reported the vaccine effectiveness against variants (Haas et al., 2021) . There was no effectiveness against mild-to-moderate Covid-19 due to B.1.351 variant (VE=21.9%, 95%CI, after two doses of the ChAdOx1 nCoV-19 vaccine (Madhi et al., 2021) (Li et al., 2021) . A single dose of the Ad26.COV2.S also showed 68.1% (95%CI, 48.8 to 80.7) effectiveness against the P.1 variant to prevent moderate to severe COVID-19 (Sadoff et al., 2021) . The estimates of VE against SARS-CoV-2 variants in real-world settings are scarce, so we are not yet to evaluate VE with the variants, what we need to do next. Studies in the real-world around the world have shown that the proved vaccines are highly protective against SARS-CoV-2, therefore, we should be fully vaccinated according to the standard schedule to achieve maximum VE. It is worth noting that vaccination cannot eliminate the risk of infections (Brosh-Nissimov et al., 2021) , and preventive and control measures should be taken seriously, especially for the high-risk groups. Consistent with the results of phase III clinical trials, the authorized vaccines are highly protective against SARS-CoV-2 in the real-world settings. Besides, the actual VE depends on not only the effectiveness of the vaccine itself but also on the vaccinated population and status. Preventive measures remain essential. This study does not require ethical approval because the meta-analysis is based on published research, and the original data are anonymous. References: 'metafor' P. Package 'metafor' National Study Group for C-V. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants Effectiveness and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization Vaccination in the elderly: The challenge of immune changes with aging mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting Effectiveness of COVID-19 vaccines: From clinical trials to real life Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines (Basel) Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using 19 national surveillance data Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection Spread of a Variant SARS-CoV-2 in Long-Term Care Facilities in England Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study Interpreting vaccine effectiveness trial results for infection and transmission Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults 20 in England: test negative case-control study Effectiveness of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial The PRISMA 2020 statement: an updated guideline for reporting systematic reviews Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Effectiveness and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a study protocol for a randomised controlled trial Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization FDA-authorized mRNA COVID-19 vaccines are effective per 21 real-world evidence synthesized across a multi-state health system A systematic review assessing the under-representation of elderly adults in COVID-19 trials Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study Proportion of SARS-CoV-2 positive tests and vaccination in Veterans Affairs Community Living Centers Safety and Effectiveness of Single-Dose Ad26.COV2.S Vaccine against Covid-19 Efectividad de la vacuna CoronaVac con virus inactivo contra SARS-CoV-2 en Chile VIVALDI): a prospective cohort study. The Lancet Infectious Diseases Safety and Effectiveness of the BNT162b2 mRNA Covid-19 Vaccine Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) -United States -2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses Tracking SARS-CoV-2 variants Retrieved Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention BNT162b2 Vaccine Effectiveness in Preventing Asymptomatic Infection With SARS-CoV-2 Virus: A Nationwide Historical Cohort Study The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study The authors are very thankful to everyone who participated in this study. Weidong Zhang, Caifang Zheng and Weihao Shao designed the study. Caifang Zheng and Weihao Shao designed the search strategies and performed the literature search.Xiaorui Chen, Bowen Zhang and Gaili Wang reviewed the literature and extracted the available data. Caifang Zheng and Weihao Shao analyzed the data and wrote the paper.All authors approved the submitted and final versions. The authors declare no conflict of interest. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.